Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor
- PMID: 8443402
- DOI: 10.1007/BF01961247
Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor
Abstract
The binding characteristics of several cytotoxic analogs of luteinizing hormone-releasing hormone (LH-RH) developed in our laboratory were examined in membranes from human breast cancer and estrogen independent MXT mammary cancer. Specific binding of [125I]D-Trp6-LH-RH and the cytotoxic LH-RH analog [125I]T-98 ([D-Lys6]LH-RH coupled to glutaryl-2-(hydroxymethyl)anthraquinone) (HMAQG) was demonstrated in membrane preparations from human breast and MXT mammary tumor cells. Ligand binding of T-98 was specific, saturable, and dependent on temperature, time, and plasma membrane concentration. Analysis of the binding data showed that in human breast cancer, interaction of [125I]T-98 was consistent with the presence of two classes of LH-RH receptors, one class showing high affinity and low capacity, and the other class showing low affinity and high capacity binding. In membranes from MXT mammary cancer, T-98 bound to one class of saturable, specific, noncooperative binding sites with high affinity and low capacity. The rates of association and dissociation for [125I]T-98 were calculated to be 4.757 x 10(8) M-1 min-1 and 0.016 min-1 (t1/2 = 38.7) in membranes from MXT mammary cancer. In human breast cancer, association rate constants (K1a and K1b) were 2.3 x 10(6) M-1 min-1 for binding to high affinity and 1.8 x 10(4) M-1 min-1 for binding to low affinity binding sites. Dissociation rate constants were K-1a = 0.0801 min-1 (t1/2a = 63.4 min) and K-1b = 0.0467 min-1 (t1/2b = 23.5 min), respectively. [125I]T-98 was not displaced by either unlabeled somatostatin or epidermal growth factor, but was displaced completely by unlabeled T-98 or [D-Trp6]LH-RH. The analysis of displacement curves of [D-Trp6]LH-RH by cytotoxic agonists and antagonists of LH-RH synthesized in our laboratory showed that T-121, AJ-11, T-120, T-133, and T-98 were the most potent in displacing [125I]D-Trp6-LH-RH from breast and MXT cancer membranes. Binding kinetics and analyses of displacement curves of [125I]D-Trp6-LH-RH and [125I]T-98 in membranes of human breast cancer and estrogen independent MXT mouse mammary cancer suggest that binding of the cytotoxic analog T-98 to the LH-RH receptor proceeds reversibly like that of its congeners without cytotoxic radicals. Our findings may provide a stimulus for further studies with LH-RH analogs carrying cytotoxic radicals.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.J Cancer Res Clin Oncol. 1993;119(5):273-8. doi: 10.1007/BF01212725. J Cancer Res Clin Oncol. 1993. PMID: 8382705 Free PMC article.
-
Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.Proc Soc Exp Biol Med. 1989 Dec;192(3):209-18. doi: 10.3181/00379727-192-42987. Proc Soc Exp Biol Med. 1989. PMID: 2574866
-
Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.Cancer Res. 1990 Mar 15;50(6):1841-6. Cancer Res. 1990. PMID: 2155060
-
Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1061-7. doi: 10.1016/0960-0760(90)90466-x. J Steroid Biochem Mol Biol. 1990. PMID: 1981009 Review.
-
LH-RH agonists and antagonists.Int J Gynaecol Obstet. 1980;18(5):318-24. doi: 10.1002/j.1879-3479.1980.tb00507.x. Int J Gynaecol Obstet. 1980. PMID: 6110575 Review.
Cited by
-
Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.J Cancer Res Clin Oncol. 1993;119(5):273-8. doi: 10.1007/BF01212725. J Cancer Res Clin Oncol. 1993. PMID: 8382705 Free PMC article.
-
A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy.Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11081-4. doi: 10.1073/pnas.96.20.11081. Proc Natl Acad Sci U S A. 1999. PMID: 10500132 Free PMC article.
-
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer.Breast Cancer (Dove Med Press). 2018 Mar 6;10:39-49. doi: 10.2147/BCTT.S137508. eCollection 2018. Breast Cancer (Dove Med Press). 2018. PMID: 29551913 Free PMC article. Review.
-
Antitumour effect of a gonadotropin-releasing-hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts.J Cancer Res Clin Oncol. 1994;120(10):578-84. doi: 10.1007/BF01212811. J Cancer Res Clin Oncol. 1994. PMID: 7929528 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous